ProMIS Neurosciences (PMN) Enterprise Value (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Enterprise Value came in at -$63.8 million in Q1 2026, down 660.34% YoY from $11.4 million in Q1 2025, and down 938.13% on a QoQ basis from -$6.2 million in Q4 2025.
ProMIS Neurosciences (PMN) Enterprise Value (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Enterprise Value data on file, last reported at -$63.8 million in Q1 2026.
- Quarterly Enterprise Value fell 660.34% year-over-year to -$63.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$63.8 million (down 660.34% YoY) and the FY2025 annual result came in at -$6.2 million, up 53.84% from the prior year.
- Enterprise Value slipped to -$63.8 million in Q1 2026, from -$6.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.0 million in Q2 2024 to a low of -$63.8 million in Q1 2026.
- A 5-year average of -$11.9 million and a median of -$7.3 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 85.96% — and 2026, when it plunged 660.34%.
- Tracing PMN's Enterprise Value over 5 years: stood at -$5.9 million in 2022, then slumped by 113.83% to -$12.6 million in 2023, then slipped by 5.49% to -$13.3 million in 2024, then jumped by 53.84% to -$6.2 million in 2025, then plunged by 938.13% to -$63.8 million in 2026.
- The last three Enterprise Value figures came in at -$63.8 million (Q1 2026), -$6.2 million (Q4 2025), and -$15.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | -53.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.46 Mn |
| Mar 31, 2026 | -63.85 Mn |
| Dec 31, 2025 | -6.15 Mn |
| Sep 30, 2025 | -15.43 Mn |
| Jun 30, 2025 | -4.54 Mn |
| Mar 31, 2025 | -8.40 Mn |
| Dec 31, 2024 | -13.32 Mn |
| Sep 30, 2024 | -21.57 Mn |
| Jun 30, 2024 | -1.02 Mn |
| Mar 31, 2024 | -2.53 Mn |
| Dec 31, 2023 | -12.63 Mn |
| Sep 30, 2023 | -16.90 Mn |
| Jun 30, 2023 | -1.25 Mn |
| Mar 31, 2023 | -3.36 Mn |
| Dec 31, 2022 | -5.91 Mn |
| Sep 30, 2022 | -3.95 Mn |
| Jun 30, 2022 | -8.94 Mn |
| Dec 31, 2021 | -16.98 Mn |